NZ603615A - Antibodies that bind to il-18 and methods of purifying the same - Google Patents

Antibodies that bind to il-18 and methods of purifying the same

Info

Publication number
NZ603615A
NZ603615A NZ603615A NZ60361509A NZ603615A NZ 603615 A NZ603615 A NZ 603615A NZ 603615 A NZ603615 A NZ 603615A NZ 60361509 A NZ60361509 A NZ 60361509A NZ 603615 A NZ603615 A NZ 603615A
Authority
NZ
New Zealand
Prior art keywords
sample
hcp
antibody
hic
antigen binding
Prior art date
Application number
NZ603615A
Inventor
Robert K Hickman
Qing Huang
Johanna Gervais
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Priority claimed from NZ592094A external-priority patent/NZ592094A/en
Publication of NZ603615A publication Critical patent/NZ603615A/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed is a pharmaceutical composition comprising: (a) an HCP-reduced anti-IL-18 antibody, or antigen binding portion thereof, preparation produced by: (1) subjecting a sample mixture comprising an anti-IL-18 antibody, or antigen binding portion thereof, and at least one HCP, to a reduction in pH thus forming a primary recovery sample, wherein said reduction in pH is between about 3.0 to about 4.0; (2) adjusting said primary recovery sample to a pH between about 4.5 to about 5.5 and a conductivity of 9 ± 0.5 mS/cm followed by; (3) applying said primary recovery sample to cation exchange resin and collecting cation exchange sample; (4) applying said cation exchange sample to a hydrophobic interactive chromatography (HIC) resin and collecting an HIC sample, wherein said HIC sample comprises said HCP-reduced anti-IL-18 antibody, or antigen binding portion thereof, preparation; (b) and a pharmaceutically acceptable carrier.
NZ603615A 2008-10-20 2009-10-20 Antibodies that bind to il-18 and methods of purifying the same NZ603615A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19675108 2008-10-20
NZ592094A NZ592094A (en) 2008-10-20 2009-10-20 Antibodies that bind to il-18 and methods of purifying the same

Publications (1)

Publication Number Publication Date
NZ603615A true NZ603615A (en) 2014-06-27

Family

ID=51022577

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ603615A NZ603615A (en) 2008-10-20 2009-10-20 Antibodies that bind to il-18 and methods of purifying the same

Country Status (1)

Country Link
NZ (1) NZ603615A (en)

Similar Documents

Publication Publication Date Title
NZ592094A (en) Antibodies that bind to il-18 and methods of purifying the same
NZ603619A (en) Antibodies that bind to il-12 and methods of purifying the same
NZ599100A (en) Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
NZ592095A (en) Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
WO2008074004A3 (en) Human antibodies that bind cd70 and uses thereof
WO2005035584A8 (en) Fully human antibodies against human 4-1bb (cd137)
WO2004022718A3 (en) Therapeutic human anti-il-1r1 monoclonal antibody
AU9399501A (en) Therapeutic antibodies
WO2008070569A3 (en) Human antibodies that bind cd22 and uses thereof
UA94576C2 (en) Isolated antibody that binds to igf-1r, composition and methods relating to anti-igf-1 receptor antibodies
WO2009054863A3 (en) Human antibodies that bind cd19 and uses thereof
EP1874820A4 (en) High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
WO2013054331A8 (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2007065433A3 (en) Anti-orthopoxvirus recombinant polyclonal antibody
IL198379A (en) Humanized antibodies and antibody fragments that specifically bind sphingosine-1-phosphate, nucleic acids encoding the same and compositions and methods for use thereof to treat disease
WO2004010947A3 (en) Humanized antibodies against human 4-1bb
AR067199A1 (en) PROTEINS OF UNION TO ANTIGENS THAT JOIN PAR-2
WO2008060367A3 (en) Human antibodies that bind cxcr4 and uses thereof
NZ717429A (en) Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
WO2009004822A1 (en) ANTI-Muc17 ANTIBODY
NO20080012L (en) Methods for treating brain tumors with antibodies
WO2006116442A3 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
WO2007023298A3 (en) Antibodies
WO2007109742A3 (en) Methods for humanizing antibodies and humanized antibodies made thereby

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: ABBVIE INC., US

Effective date: 20140327

S23 Proceedings under section 23: mention of inventor as such in patent

Free format text: INVENTOR GERVAIS, JOHANNA, HICKMAN, ROBERT, K., HUANG, QING ADDED

Effective date: 20140605

PSEA Patent sealed
LAPS Patent lapsed